Recap: Epizyme Q2 Earnings

Shares of Epizyme EPZM were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 9.43% over the past year to ($0.58), which beat the estimate of ($0.61).

Revenue of $2,467,000 decreased by 58.19% from the same period last year, which missed the estimate of $4,300,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Price Action

Company's 52-week high was at $27.82

Company's 52-week low was at $9.73

Price action over last quarter: down 21.35%

Company Description

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.